Patents by Inventor Cristina FREIRE
Cristina FREIRE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230277466Abstract: The present invention provides for a formulation comprising an active alkaline phosphatase (AP)-based agent and an enteric agent, wherein the formulation is suitable for releasing a substantial amount of the active AP-based agent in the intestines.Type: ApplicationFiled: March 17, 2023Publication date: September 7, 2023Inventors: Andrew BRISTOL, Ray STAPLETON, Michael KALEKO, Christian FURLAN FREGUIA, Steven HUBERT, Cristina FREIRE, James GUBBINS
-
Patent number: 11638699Abstract: The present invention provides for a formulation comprising an active alkaline phosphatase (AP)-based agent and an enteric agent, wherein the formulation is suitable for releasing a substantial amount of the active AP-based agent in the intestines.Type: GrantFiled: March 20, 2019Date of Patent: May 2, 2023Assignee: Theriva Biologics, Inc.Inventors: Andrew Bristol, Ray Stapleton, Michael Kaleko, Christian Furlan Freguia, Steven Hubert, Cristina Freire, James Gubbins
-
Patent number: 11534406Abstract: In a delayed release formulation comprising a core containing a drug and a delayed release coating for providing intestinal release, release of the drug in the colon is accelerated by including an isolation layer between the core and the delayed release coating. The delayed release coating comprises an inner layer and an outer layer. The outer layer comprises a pH dependently soluble polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a soluble polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said soluble polymeric material being selected from the group consisting of a polycarboxylic acid polymer that is at least partially neutralised, and a non-ionic polymer, provided that, where said soluble polymeric material is a non-ionic polymer, said inner layer comprises at least one additive selected from a buffer agent and a base.Type: GrantFiled: March 18, 2020Date of Patent: December 27, 2022Assignee: Tillotts Pharma AGInventors: Felipe José Oliveira Varum, Roberto Carlos Bravo González, Thomas Buser, Abdul Waseh Basit, Ana Cristina Freire
-
Patent number: 11517534Abstract: In a delayed release formulation comprising a core containing a drug and a delayed release coating for providing intestinal release, release of the drug in the colon is accelerated by including an isolation layer between the core and the delayed release coating. The delayed release coating comprises an inner layer and an outer layer. The outer layer comprises a pH dependently soluble polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a soluble polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said soluble polymeric material being selected from the group consisting of a polycarboxylic acid polymer that is at least partially neutralised, and a non-ionic polymer, provided that, where said soluble polymeric material is a non-ionic polymer, said inner layer comprises at least one additive selected from a buffer agent and a base.Type: GrantFiled: June 2, 2017Date of Patent: December 6, 2022Assignee: Tillotts Pharma AGInventors: Felipe Josè Oliveira Varum, Roberto Carlos Bravo González, Thomas Buser, Abdul Waseh Basit, Ana Cristina Freire
-
Publication number: 20220323367Abstract: The present invention provides, in part, formulations comprising an alkaline phosphatase. Particularly, modified-release formulations comprising an alkaline phosphatase are provided, which release a substantial amount of the alkaline phosphatase in the intestines. Therapeutic uses of the alkaline phosphatase formulations are also provided.Type: ApplicationFiled: June 3, 2020Publication date: October 13, 2022Inventors: Michael KALEKO, Ray STAPLETON, Andrew BRISTOL, Steven HUBERT, Cristina FREIRE
-
Publication number: 20210030686Abstract: The present invention provides for a formulation comprising an active alkaline phosphatase (AP)-based agent and an enteric agent, wherein the formulation is suitable for releasing a substantial amount of the active AP-based agent in the intestines.Type: ApplicationFiled: March 20, 2019Publication date: February 4, 2021Inventors: Andrew BRISTOL, Ray STAPLETON, Michael KALEKO, Christian FURLAN FREGUIA, Steven HUBERT, Cristina FREIRE, James GUBBINS
-
Patent number: 10799515Abstract: In a delayed release formulation comprising a core containing a drug and a delayed release coating for providing intestinal release, release of the drug in the colon is accelerated by including an isolation layer between the core and the delayed release coating. The delayed release coating comprises an inner layer and an outer layer. The outer layer comprises a pH dependently soluble polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a soluble polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said soluble polymeric material being selected from the group consisting of a polycarboxylic acid polymer that is at least partially neutralised, and a non-ionic polymer, provided that, where said soluble polymeric material is a non-ionic polymer, said inner layer comprises at least one additive selected from a buffer agent and a base.Type: GrantFiled: October 29, 2013Date of Patent: October 13, 2020Assignee: TILLOTTS PHARMA AGInventors: Felipe Jose Oliveira Varum, Roberto Carlos Bravo Gonzalez, Thomas Buser, Abdul Waseh Basit, Ana Cristina Freire
-
Publication number: 20200214987Abstract: In a delayed release formulation comprising a core containing a drug and a delayed release coating for providing intestinal release, release of the drug in the colon is accelerated by including an isolation layer between the core and the delayed release coating. The delayed release coating comprises an inner layer and an outer layer. The outer layer comprises a pH dependently soluble polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a soluble polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said soluble polymeric material being selected from the group consisting of a polycarboxylic acid polymer that is at least partially neutralised, and a non-ionic polymer, provided that, where said soluble polymeric material is a non-ionic polymer, said inner layer comprises at least one additive selected from a buffer agent and a base.Type: ApplicationFiled: March 18, 2020Publication date: July 9, 2020Applicant: Tillotts Pharma AGInventors: Felipe José OLIVEIRA VARUM, Roberto Carlos Bravo González, Thomas Buser, Abdul Waseh Basit, Ana Cristina Freire
-
Patent number: 10272048Abstract: In a delayed release formulation comprising a core containing a drug and a delayed release coating for providing intestinal release, release of the drug in the colon is accelerated by including an isolation layer between the core and the delayed release coating. The delayed release coating comprises an inner layer and an outer layer. The outer layer comprises a pH dependently soluble polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a soluble polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said soluble polymeric material being selected from the group consisting of a polycarboxylic acid polymer that is at least partially neutralized, and a non-ionic polymer, provided that, where said soluble polymeric material is a non-ionic polymer, said inner layer comprises at least one additive selected from a buffer agent and a base.Type: GrantFiled: September 16, 2016Date of Patent: April 30, 2019Assignee: Tillotts Pharma AGInventors: Felipe Josè Oliveira Varum, Roberto Carlos Bravo González, Thomas Buser, Abdul Waseh Basit, Ana Cristina Freire
-
Patent number: 10226430Abstract: Delayed release of a drug to the colon is achieved from a delayed release formulation comprising a core and a coating for the core. The core comprises a drug and the coating comprises an inner layer and an outer layer. The outer layer comprises a mixture of a first polymeric material which is susceptible to attack by colonic bacteria, and a second polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a third polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said third polymeric material being selected from an at least partially neutralized polycarboxylic acid and a non-ionic polymer. In embodiments in which the third polymeric material is a non-ionic polymer, the inner layer comprises at least one of a buffer agent and a base.Type: GrantFiled: April 29, 2013Date of Patent: March 12, 2019Assignee: TILLOTTS PHARMA AGInventors: Roberto Carlos Bravo Gonzalez, Thomas Buser, Frederic Jean-Claude Goutte, Abdul Waseh Basit, Felipe Jose Oliveira Varum, Ana Cristina Freire
-
Publication number: 20170266117Abstract: In a delayed release formulation comprising a core containing a drug and a delayed release coating for providing intestinal release, release of the drug in the colon is accelerated by including an isolation layer between the core and the delayed release coating. The delayed release coating comprises an inner layer and an outer layer. The outer layer comprises a pH dependently soluble polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a soluble polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said soluble polymeric material being selected from the group consisting of a polycarboxylic acid polymer that is at least partially neutralised, and a non-ionic polymer, provided that, where said soluble polymeric material is a non-ionic polymer, said inner layer comprises at least one additive selected from a buffer agent and a base.Type: ApplicationFiled: June 2, 2017Publication date: September 21, 2017Applicant: Tillotts Phharma AGInventors: Felipe Josè OLIVEIRA VARUM, Roberto Carlos BRAVO GONZÁLEZ, Thomas BUSER, Abdul Waseh BASIT, Ana Cristina FREIRE
-
Publication number: 20170035698Abstract: In a delayed release formulation comprising a core containing a drug and a delayed release coating for providing intestinal release, release of the drug in the colon is accelerated by including an isolation layer between the core and the delayed release coating. The delayed release coating comprises an inner layer and an outer layer. The outer layer comprises a pH dependently soluble polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a soluble polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said soluble polymeric material being selected from the group consisting of a polycarboxylic acid polymer that is at least partially neutralised, and a non-ionic polymer, provided that, where said soluble polymeric material is a non-ionic polymer, said inner layer comprises at least one additive selected from a buffer agent and a base.Type: ApplicationFiled: September 16, 2016Publication date: February 9, 2017Applicant: Tillotts Pharma AGInventors: Felipe Josè OLIVEIRA VARUM, Roberto Carlos BRAVO GONZÁLEZ, Thomas BUSER, Abdul Waseh BASIT, Ana Cristina FREIRE
-
Publication number: 20160250232Abstract: In a delayed release formulation comprising a core containing a drug and a delayed release coating for providing intestinal release, release of the drug in the colon is accelerated by including an isolation layer between the core and the delayed release coating. The delayed release coating comprises an inner layer and an outer layer. The outer layer comprises a pH dependently soluble polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a soluble polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said soluble polymeric material being selected from the group consisting of a polycarboxylic acid polymer that is at least partially neutralised, and a non-ionic polymer, provided that, where said soluble polymeric material is a non-ionic polymer, said inner layer comprises at least one additive selected from a buffer agent and a base.Type: ApplicationFiled: October 29, 2013Publication date: September 1, 2016Applicant: TILLOTTS PHARMA AGInventors: Felipe Jose Oliveira VARUM, Roberto Carlos BRAVO GONZALEZ, Thomas BUSER, Abdul Waseh BASIT, Ana Cristina FREIRE
-
Patent number: 9364440Abstract: Delayed release of a drug to the colon is achieved from a delayed release formulation comprising a core and a coating for the core. The core comprises a drug and the coating comprises an outer layer and at least one layer between the core and the outer layer selected from the group consisting of an isolation layer and an inner layer. The outer layer comprises a mixture of a first polymeric material which is susceptible to attack by colonic bacteria, and a second polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a third polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said third polymeric material being selected from an at least partially neutralised polycarboxylic acid and a non-ionic polymer. In embodiments in which the third polymeric material is a non-ionic polymer, the inner layer comprises at least one of a buffer agent and a base.Type: GrantFiled: April 29, 2013Date of Patent: June 14, 2016Assignee: TILLOTTS PHARMA AGInventors: Roberto Carlos Bravo Gonzalez, Thomas Buser, Frederic Jean-Claude Goutte, Abdul Waseh Basit, Felipe Jose Oliveira Varum, Ana Cristina Freire
-
Publication number: 20150132380Abstract: Delayed release of a drug to the colon is achieved from a delayed release formulation comprising a core and a coating for the core. The core comprises a drug and the coating comprises an outer layer and at least one layer between the core and the outer layer selected from the group consisting of an isolation layer and an inner layer. The outer layer comprises a mixture of a first polymeric material which is susceptible to attack by colonic bacteria, and a second polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a third polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said third polymeric material being selected from an at least partially neutralised polycarboxylic acid and a non-ionic polymer. In embodiments in which the third polymeric material is a non-ionic polymer, the inner layer comprises at least one of a buffer agent and a base.Type: ApplicationFiled: April 29, 2013Publication date: May 14, 2015Applicant: TILLOTTS PHARMA AGInventors: Roberto Carlos Bravo Gonzalez, Thomas Buser, Frederic Jean-Claude Goutte, Abdul Waseh Basit, Felipe Jose Oliveira Varum, Ana Cristina Freire
-
Publication number: 20150125525Abstract: Delayed release of a drug to the colon is achieved from a delayed release formulation comprising a core and a coating for the core. The core comprises a drug and the coating comprises an inner layer and an outer layer. The outer layer comprises a mixture of a first polymeric material which is susceptible to attack by colonic bacteria, and a second polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a third polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said third polymeric material being selected from an at least partially neutralised polycarboxylic acid and a non-ionic polymer. In embodiments in which the third polymeric material is a non-ionic polymer, the inner layer comprises at least one of a buffer agent and a base.Type: ApplicationFiled: April 29, 2013Publication date: May 7, 2015Applicant: TILLOTTS PHARMA AGInventors: Roberto Carlos Bravo Gonzalez, Thomas Buser, Frederic Goutte, Abdul Waseh Basit, Felipe Jose, Oliveira Varum, Ana Cristina Freire
-
Publication number: 20030036476Abstract: In a coated catalyst having a core and at least one shell surrounding the core, the core is made up of an inert support material, the shell or shells is/are made up of a porous support substance, with the shell being attached physically to the core, and a catalytically active metal selected from the group consisting of the metals of the 10th and 11th groups of the Periodic Table of the Elements is present in finely divided form or a precursor of the catalytically active metal is present in uniformly distributed form in the shell or shells.Type: ApplicationFiled: September 10, 2002Publication date: February 20, 2003Inventors: Heiko Arnold, Cristina Freire Erdbrugger, Thomas Heidemann, Gerald Meyer, Signe Unverricht, Andrea Frenzel, Joachim Wulff-Doring, Andreas Ansmann
-
Catalyst and process for the selective hydrogenation of unsaturated compounds in hydrocarbon streams
Patent number: 6350717Abstract: A catalyst comprising at least one metal of the 10th group of the Periodic Table of the Elements and at least one metal of the 11th group of the Periodic Table of the Elements on an aluminum oxide support, wherein the metal or metals of the 10th group is or are essentially concentrated in an outer layer close to the surface of the catalyst particle, the metal or metals of the 11th group is or are distributed essentially uniformly over the volume of the catalyst particle and the weight ratio of the metal or metals of the 11th group to the metal or metals of the 10th group is not more than 1.95.Type: GrantFiled: August 30, 1999Date of Patent: February 26, 2002Assignee: BASF AktiengesellschaftInventors: Andrea Frenzel, Cristina Freire Erdbrügger, Ekkehard Schwab, Michael Hesse, Gerd Linden, Herbert Wanjek, Hans-Martin Allmann -
Patent number: 6297415Abstract: A catalyst packing which can be produced by vapor deposition and/or sputtering of at least one substance active as catalyst and/or promotor onto woven or knitted fabrics or sheets as support material is used in a process for catalytic distillation in which a heterogeneously catalyzed reaction is combined with a simultaneous distillation or rectification over the catalyst packing.Type: GrantFiled: June 24, 1999Date of Patent: October 2, 2001Assignee: BASF AktiengesellschaftInventors: Franz Josef Bröcker, Klemens Flick, Cristina Freire Erdbrügger, Gerd Kaibel, Gerald Meyer, Hans-Joachim Müller, Peter Polanek, Ekkehard Schwab
-
Patent number: 6201160Abstract: Alcohols are prepared by the catalytic hydrogenation of the corresponding carbonyl compounds at elevated temperatures and at superatmospheric pressure in the liquid phase by a process in which the catalyst used contains copper on an SiO2-containing carrier in the presence or absence of one or more of the elements magnesium, barium, zinc and chromium.Type: GrantFiled: November 19, 1996Date of Patent: March 13, 2001Assignee: BASF AktiengesellschaftInventors: Martin Brudermüller, Matthias Irgang, Martin Schmidt-Radde, Franz Merger, Tom Witzel, Detlef Kratz, Eckehard Danz, Arnold Wittwer, Michael Hesse, Manfred Sauerwald, Cristina Freire Erdbrügger